Director buys 111,111 Eikon Therapeutics shares at $18
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Eikon Therapeutics director Kenneth C. Frazier bought 111,111 shares of the company’s common stock in an open-market transaction. The purchase took place on February 4, 2026 at a price of $18 per share, and he now directly holds 111,111 shares.
Insider Trade Summary
Net Buyer: 111,111 shares
Net Buy
1 txn
Insider
FRAZIER KENNETH C
Role
Director
Bought
111,111 shs ($2.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 111,111 | $18.00 | $2.00M |
Holdings After Transaction:
Common Stock — 111,111 shares (Direct)
Holdings Before and After:
Common Stock, 0 to 111,111 shares (Direct)
Other Insiders: 3 other insiders reported open-market purchases of this stock in the 30 days up to this filing.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Eikon Therapeutics (EIKN) report for February 4, 2026?
Eikon Therapeutics reported that director Kenneth C. Frazier purchased 111,111 shares of common stock on February 4, 2026. The transaction was an open-market purchase at a price of $18 per share, increasing his direct holdings.
Is the Eikon Therapeutics insider transaction a buy or sell by the director?
The transaction is a buy. Director Kenneth C. Frazier executed an open-market purchase of 111,111 shares of Eikon Therapeutics common stock at $18 per share on February 4, 2026, classified with transaction code P.
AI-generated analysis. How Rhea-AI works. Not financial advice.